![HSDT - Helius Medical Technologies Inc - Stock Price Chart](https://charts2-node.finviz.com/chart.ashx?cs=l&t=HSDT&tf=d&s=linear&ct=candle_stick&tm=d&o[0][ot]=sma&o[0][op]=50&o[0][oc]=FF8F33C6&o[1][ot]=sma&o[1][op]=200&o[1][oc]=DCB3326D&o[2][ot]=sma&o[2][op]=20&o[2][oc]=DC32B363&o[3][ot]=patterns&o[3][op]=&o[3][oc]=000) |
Market Cap | 2.08M | EPS (ttm) | -12.96 |
P/E | - | EPS this Y | 62.43% |
Forward P/E | - | EPS next Y | 44.97% |
PEG | - | EPS past 5Y | 63.34% |
P/S | 3.11 | EPS next 5Y | - |
P/B | 0.31 | EPS Q/Q | 30.36% |
Dividend | - | Sales Q/Q | 21.62% |
Insider Own | 1.79% | Inst Own | 0.89% |
Insider Trans | 0.00% | Inst Trans | - |
Short Float | 1.51% | Earnings | May 13/a |
Analyst Recom | 1.00 | Target Price | 4.00 |
Avg Volume | 395.47K | 52W Range | 0.77 - 13.43 |
|
|
|
Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain's ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded in 2014 and is headquartered in Newtown, PA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
ANDREEFF DANE | President and CEO | Dec 14 '23 | Buy | 8.10 | 5,000 | 40,475 | 16,512 | Dec 15 07:00 AM | ANDREEFF DANE | President and CEO | Dec 01 '23 | Buy | 6.45 | 2,006 | 12,935 | 13,685 | Dec 04 08:30 AM | ANDREEFF DANE | President and CEO | Nov 30 '23 | Buy | 6.37 | 2,000 | 12,741 | 12,551 | Dec 04 08:30 AM | ANDREEFF DANE | President and CEO | Aug 30 '23 | Buy | 7.64 | 5,000 | 38,212 | 11,420 | Aug 30 08:42 PM | ANDREEFF DANE | President and CEO | Aug 28 '23 | Buy | 6.37 | 5,078 | 32,339 | 8,774 | Aug 30 08:42 PM |
|
|
![](gfx/nic2x2.gif) |
![PSIG - PS International Group Ltd. - Stock Price Chart](https://charts2-node.finviz.com/chart.ashx?cs=l&t=PSIG&tf=d&s=linear&ct=candle_stick&tm=d&o[0][ot]=sma&o[0][op]=50&o[0][oc]=FF8F33C6&o[1][ot]=sma&o[1][op]=200&o[1][oc]=DCB3326D&o[2][ot]=sma&o[2][op]=20&o[2][oc]=DC32B363&o[3][ot]=patterns&o[3][op]=&o[3][oc]=000) |
Market Cap | 5.13M | EPS (ttm) | -0.31 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | 0.88 | EPS Q/Q | -4508.33% |
Dividend | - | Sales Q/Q | - |
Insider Own | 76.39% | Inst Own | 22.34% |
Insider Trans | 0.00% | Inst Trans | - |
Short Float | - | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 193.44K | 52W Range | 1.55 - 12.25 |
|
|
PS International Group Ltd. engages in providing logistics and supply chain solutions. The company was founded on September 12, 2023 and is headquartered in Hong Kong. |
|
![](gfx/nic2x2.gif) |
![GDTC - CytoMed Therapeutics Ltd - Stock Price Chart](https://charts2-node.finviz.com/chart.ashx?cs=l&t=GDTC&tf=d&s=linear&ct=candle_stick&tm=d&o[0][ot]=sma&o[0][op]=50&o[0][oc]=FF8F33C6&o[1][ot]=sma&o[1][op]=200&o[1][oc]=DCB3326D&o[2][ot]=sma&o[2][op]=20&o[2][oc]=DC32B363&o[3][ot]=patterns&o[3][op]=&o[3][oc]=000) |
Market Cap | 20.89M | EPS (ttm) | -0.27 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | 2.45 | EPS Q/Q | 9.49% |
Dividend | - | Sales Q/Q | - |
Insider Own | 59.01% | Inst Own | 0.00% |
Insider Trans | 0.00% | Inst Trans | - |
Short Float | 0.82% | Earnings | May 29 |
Analyst Recom | 1.00 | Target Price | 5.00 |
Avg Volume | 71.92K | 52W Range | 1.88 - 5.50 |
|
|
|
CytoMed Therapeutics Ltd. is a biopharmaceutical company, which engages in the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy, and undertaking the research and development of immune cell and stem cell-based therapy. It operates through the Malaysia and Singapore geographical segments. The company was founded by Chee Kong Choo on March 9, 2018 and is headquartered in Singapore. |
|
| ![](gfx/nic2x2.gif) |
![CCTG - CCSC Technology International Holdings Ltd - Stock Price Chart](https://charts2-node.finviz.com/chart.ashx?cs=l&t=CCTG&tf=d&s=linear&ct=candle_stick&tm=d&o[0][ot]=sma&o[0][op]=50&o[0][oc]=FF8F33C6&o[1][ot]=sma&o[1][op]=200&o[1][oc]=DCB3326D&o[2][ot]=sma&o[2][op]=20&o[2][oc]=DC32B363&o[3][ot]=patterns&o[3][op]=&o[3][oc]=000) |
Market Cap | 18.56M | EPS (ttm) | -0.01 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | 9.87 | EPS next 5Y | - |
P/B | 12.16 | EPS Q/Q | -159.43% |
Dividend | - | Sales Q/Q | -53.44% |
Insider Own | 82.42% | Inst Own | 0.00% |
Insider Trans | 0.00% | Inst Trans | - |
Short Float | 1.81% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 64.76K | 52W Range | 1.75 - 30.00 |
|
|
|
CCSC Technology International Holdings Ltd. operates as a holding company with interests in the designing, manufacturing and sale of interconnect products. Its products include connectors, cables and wire harnesses. The company was founded by Chi Sing Chiu on October 19, 2021 and is headquartered in Hong Kong. |
|
![](gfx/nic2x2.gif) |
![ABVE - Above Food Ingredients Inc. - Stock Price Chart](https://charts2-node.finviz.com/chart.ashx?cs=l&t=ABVE&tf=d&s=linear&ct=candle_stick&tm=d&o[0][ot]=sma&o[0][op]=50&o[0][oc]=FF8F33C6&o[1][ot]=sma&o[1][op]=200&o[1][oc]=DCB3326D&o[2][ot]=sma&o[2][op]=20&o[2][oc]=DC32B363&o[3][ot]=patterns&o[3][op]=&o[3][oc]=000) |
Market Cap | 11.68M | EPS (ttm) | -0.02 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | 0.55 | EPS Q/Q | 96.65% |
Dividend | - | Sales Q/Q | - |
Insider Own | 36.29% | Inst Own | 18.13% |
Insider Trans | 0.00% | Inst Trans | 5.14% |
Short Float | 2.86% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 103.28K | 52W Range | 1.55 - 13.50 |
|
|
|
Above Food Ingredients, Inc. engages in operating its subsidiaries, Bite Acquisition Corp. (Bite) and Above Food Corp. (Above Food). The Bite is a blank check company that affects a merger, stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Above Food is an ingredient company that provides food products and brands. The company was founded by Lionel Kambeitz on April 18, 2023 and is headquartered in Regina, Canada. |
|
| ![](gfx/nic2x2.gif) |
![AACI - Armada Acquisition Corp I - Stock Price Chart](https://charts2-node.finviz.com/chart.ashx?cs=l&t=AACI&tf=d&s=linear&ct=candle_stick&tm=d&o[0][ot]=sma&o[0][op]=50&o[0][oc]=FF8F33C6&o[1][ot]=sma&o[1][op]=200&o[1][oc]=DCB3326D&o[2][ot]=sma&o[2][op]=20&o[2][oc]=DC32B363&o[3][ot]=patterns&o[3][op]=&o[3][oc]=000) |
Market Cap | 68.09M | EPS (ttm) | -0.20 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | 11.14 | EPS Q/Q | -1987.50% |
Dividend | - | Sales Q/Q | - |
Insider Own | 79.09% | Inst Own | 16.14% |
Insider Trans | 0.00% | Inst Trans | 23.39% |
Short Float | 0.73% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 30.24K | 52W Range | 10.47 - 12.53 |
|
|
|
Armada Acquisition Corp. I operates as a blank check company. It was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. The company was founded on November 5, 2020 and is headquartered in Philadelphia, PA. |
|
![](gfx/nic2x2.gif) |
![KDLY - Kindly MD Inc. - Stock Price Chart](https://charts2-node.finviz.com/chart.ashx?cs=l&t=KDLY&tf=d&s=linear&ct=candle_stick&tm=d&o[0][ot]=sma&o[0][op]=50&o[0][oc]=FF8F33C6&o[1][ot]=sma&o[1][op]=200&o[1][oc]=DCB3326D&o[2][ot]=sma&o[2][op]=20&o[2][oc]=DC32B363&o[3][ot]=patterns&o[3][op]=&o[3][oc]=000) |
Market Cap | 10.69M | EPS (ttm) | -0.29 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | 3.11 | EPS next 5Y | - |
P/B | - | EPS Q/Q | -56.77% |
Dividend | - | Sales Q/Q | -28.55% |
Insider Own | 67.96% | Inst Own | - |
Insider Trans | 0.00% | Inst Trans | - |
Short Float | 0.56% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 86.39K | 52W Range | 1.90 - 4.20 |
|
|
|
Kindly MD, Inc. provides healthcare services. Its services include medication management, behavioral healthcare and alternative treatments. The firm offers evaluation and management, including chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, travel services, and hormone therapy. The company was founded by Timothy Pickett in December 2019 and is headquartered in Murray, UT. |
|
| ![](gfx/nic2x2.gif) |
![CRI - Carters Inc - Stock Price Chart](https://charts2-node.finviz.com/chart.ashx?cs=l&t=CRI&tf=d&s=linear&ct=candle_stick&tm=d&o[0][ot]=sma&o[0][op]=50&o[0][oc]=FF8F33C6&o[1][ot]=sma&o[1][op]=200&o[1][oc]=DCB3326D&o[2][ot]=sma&o[2][op]=20&o[2][oc]=DC32B363&o[3][ot]=patterns&o[3][op]=&o[3][oc]=000) |
Market Cap | 2.09B | EPS (ttm) | 6.36 |
P/E | 9.00 | EPS this Y | -9.24% |
Forward P/E | 10.19 | EPS next Y | 0.04% |
PEG | - | EPS past 5Y | 0.77% |
P/S | 0.72 | EPS next 5Y | -1.20% |
P/B | 2.49 | EPS Q/Q | 9.09% |
Dividend | 5.50% | Sales Q/Q | -4.94% |
Insider Own | 2.92% | Inst Own | 116.09% |
Insider Trans | -0.27% | Inst Trans | -3.15% |
Short Float | 15.21% | Earnings | Jul 26/b |
Analyst Recom | 3.22 | Target Price | 61.33 |
Avg Volume | 844.16K | 52W Range | 59.06 - 88.03 |
|
|
|
Carter's, Inc. engages in the business of brand marketing of young children's apparel. It operates through the following segments: the United States (US) Retail, US Wholesale, and International. The US Retail segment includes selling products through retail stores and ecommerce websites. The US Wholesale segment focuses on wholesale partners. The International segment is involved in selling in retail stores and ecommerce websites in Canada and Mexico, and to international wholesale customers and licensees. The company was founded by William Carter in 1865 and is headquartered in Atlanta, GA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Jenkins Jeff | EVP Global Marketing | Mar 13 '24 | Sale | 86.00 | 1,060 | 91,160 | 35,173 | Mar 13 04:27 PM | Hipp Mark | Director | Mar 06 '24 | Sale | 81.74 | 1,875 | 153,261 | 10,216 | Mar 22 08:46 AM | CASEY MICHAEL DENNIS | Chairman and CEO | Dec 14 '23 | Option Exercise | 68.49 | 30,000 | 2,054,700 | 479,870 | Dec 15 04:16 PM | CASEY MICHAEL DENNIS | Chairman and CEO | Dec 14 '23 | Sale | 75.00 | 89,139 | 6,685,425 | 390,731 | Dec 15 04:16 PM | D'Emilio Julie | EVP, Sales | Dec 08 '23 | Option Exercise | 68.49 | 3,400 | 232,866 | 46,183 | Dec 08 04:31 PM |
|
|
![](gfx/nic2x2.gif) |
![MXL - MaxLinear Inc - Stock Price Chart](https://charts2-node.finviz.com/chart.ashx?cs=l&t=MXL&tf=d&s=linear&ct=candle_stick&tm=d&o[0][ot]=sma&o[0][op]=50&o[0][oc]=FF8F33C6&o[1][ot]=sma&o[1][op]=200&o[1][oc]=DCB3326D&o[2][ot]=sma&o[2][op]=20&o[2][oc]=DC32B363&o[3][ot]=patterns&o[3][op]=&o[3][oc]=000) |
Market Cap | 1.06B | EPS (ttm) | -2.31 |
P/E | - | EPS this Y | -176.36% |
Forward P/E | 27.77 | EPS next Y | 154.76% |
PEG | - | EPS past 5Y | -18.83% |
P/S | 2.37 | EPS next 5Y | 14.14% |
P/B | 1.74 | EPS Q/Q | -769.50% |
Dividend | - | Sales Q/Q | -49.99% |
Insider Own | 8.31% | Inst Own | 85.06% |
Insider Trans | -0.17% | Inst Trans | -0.37% |
Short Float | 4.95% | Earnings | Jul 24/a |
Analyst Recom | 2.09 | Target Price | 22.33 |
Avg Volume | 825.71K | 52W Range | 13.43 - 35.00 |
|
|
|
MaxLinear, Inc. engages in the provision of communications systems-on-chip, or SoC, solutions used in broadband, mobile and wireline infrastructure, data center, and industrial and multi-market applications. Its products include cable broadband modems and gateways, wireline connectivity devices, radio frequency transceivers, fiber-optic modules, video set-top boxes and gateways, hybrid analog and digital televisions, direct broadcast satellite outdoor and indoor units, and power management and interface products. The company was founded by Kimihiko Imura, Curtis C. Ling and Kishore V. Seendripu on September 25, 2003 and is headquartered in Carlsbad, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
ARTUSI DANIEL A | Director | May 01 '24 | Option Exercise | 0.00 | 9,170 | 0 | 29,802 | May 03 04:09 PM | MOYER ALBERT J | Director | May 01 '24 | Option Exercise | 0.00 | 9,170 | 0 | 69,822 | May 03 04:08 PM | Tewksbury Ted L III | Director | May 01 '24 | Option Exercise | 0.00 | 9,170 | 0 | 70,726 | May 03 04:09 PM | Liu Tsu-Jae King | Director | Mar 30 '24 | Option Exercise | 0.00 | 1,933 | 0 | 17,903 | Apr 02 04:26 PM | Kwong Connie H. | Corporate Controller & PAO | Mar 04 '24 | Option Exercise | 0.00 | 1,019 | 0 | 44,745 | Mar 06 04:33 PM |
|
|
![](gfx/nic2x2.gif) |
![ATXI - Avenue Therapeutics Inc - Stock Price Chart](https://charts2-node.finviz.com/chart.ashx?cs=l&t=ATXI&tf=d&s=linear&ct=candle_stick&tm=d&o[0][ot]=sma&o[0][op]=50&o[0][oc]=FF8F33C6&o[1][ot]=sma&o[1][op]=200&o[1][oc]=DCB3326D&o[2][ot]=sma&o[2][op]=20&o[2][oc]=DC32B363&o[3][ot]=patterns&o[3][op]=&o[3][oc]=000) |
Market Cap | 2.56M | EPS (ttm) | -39.72 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | 50.07% |
P/S | - | EPS next 5Y | - |
P/B | 0.57 | EPS Q/Q | 92.40% |
Dividend | - | Sales Q/Q | - |
Insider Own | 7.38% | Inst Own | 1.99% |
Insider Trans | 0.00% | Inst Trans | - |
Short Float | 4.69% | Earnings | May 15/b |
Analyst Recom | 1.00 | Target Price | 12.00 |
Avg Volume | 80.52K | 52W Range | 2.79 - 87.00 |
|
|
|
Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, a potential alternative that could reduce the use of conventional opioids for patients suffering from acute pain. The company was founded on February 9, 2015 and is headquartered in Bay Harbor Islands, FL. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Davidow Robert L | 10% Owner | Dec 11 '23 | Sale | 0.14 | 353,000 | 49,600 | 22,000 | Dec 13 04:02 PM | Davidow Robert L | 10% Owner | Dec 11 '23 | Sale | 0.14 | 264,000 | 36,960 | 681,000 | Dec 13 04:02 PM | Fortress Biotech, Inc. | 10% Owner | Sep 08 '23 | Buy | 0.72 | 418,410 | 301,255 | 1,032,390 | Sep 12 09:02 AM | ROSENWALD LINDSAY A MD | Director | Sep 08 '23 | Buy | 0.72 | 348,675 | 251,046 | 354,318 | Sep 12 09:03 AM |
|
|
|